Language: Spanish
References: 50
Page: 383-389
PDF size: 333.05 Kb.
ABSTRACT
The thrombotic phenomenon is, in our days, the leading cause of death in developed countries and nuestro. advances in knowledge about the clotting system, phase platelet and plasma cascade, have driven the development of new diagnostic techniques that allow today to obtain a specific diagnosis of the risk factors for thrombus detection and congenital abnormalities (thrombophilias primary) The large clinical spectrum of thrombotic phenomena, such as deep vein thrombosis, thromboembolism lung (now included as a single entity in venous thromboembolic disease), coronary artery disease, carotid disease, transient ischemic attack, stroke, cerebral venous thrombosis, peripheral arterial disease, mesenteric thrombosis, renovascular disease, etc., and the long list of risk factors such as pregnancy, postpartum period, major surgery, orthopedic surgery, malignant disease, atrial fibrillation, immobilization, use of oral contraceptives or hormone replacement therapy, autoimmune diseases (such as antiphospholipid syndrome, Behcet’s disease, etc. .), obesity, atherosclerosis, sepsis, prolonged travel, diabetes mellitus, nephrotic syndrome, etc., innovation and pharmacological agents for secondary prevention of these diseases is summarized in the need for us all health professionals in the update knowledge of this disease.
Antithrombotic therapy is divided, in general, in mechanical and pharmacological measures. Among the former are: compression stockings, early ambulation, intermittent pneumatic compression, antithrombotic exercises and devices, such as placing a filter in the inferior vena cava (temporary or permanent) and stenting vasculares.
This article details the features of different pharmacological agents and covers the past, present and future of antithrombotic therapy. (For a better understanding of this paper recommends the reader review the normal coagulation system.)
REFERENCES
García-Frade LF. Sistema normal de la coagulación. En: Manual de trombosis y terapia antitrombótica. García-Frade LF. 1ª ed. México: Alfil, 2008.
Vargas P, Mora T, Hurtado R. Trombofilia. En: Manual de trombosis y terapia antitrombótica. García-Frade LF. 1ª ed. México: Alfil, 2008.
García-Frade LF, Arredondo J. Agentes antitrombóticos. En: Manual de trombosis y terapia antitrombótica. García-Frade LF. 1ª ed. México: Alfil, 2008.
García-Frade. Profilaxis antitrombótica. En: Manual de trombosis y terapia antitrombótica. García-Frade LF. 1ª ed. México: Alfil, 2008.
Schrör K. Acetylsalicylic Acid. Frankfurt: Wiley-Blackewll, 2009.
Steinhubi S, Bhatt D, Brennan D, et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med 2009;150:379-386.
Berger J, Brown D, Burke G. Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease-the Women´s Health Initiative Observational Study. Circ Cardiovasc Qual Outcomes 2009;2:78-87.
US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150:396- 404. Abstract.
Mehta S. Aspirin for prevention and treatment of cardiovascular disease. Ann Intern Med 2009;150:414-416. Abstract.
Messmore H, Jeske W, Wehrmacher W, et al. Antiplatelets agents: Current drugs and future trends. Hematol Oncol ClinN Am 2005;19:87-117.
Billett H. Antiplatelet Agents and arterial thrombosis. Clin Geriatr Med 2006;22:57-74.
Fernández J, Sadaniantz B, Sadaniantz A. Review of Antithrombotic Agents Used for Acute Coronary Syndromes in Renal Patients. Am J Kidney Dis 2003;42:446-455.
Pineo G, Hull R. Vitamin K Antagonists and Direct Thrombin Inhibitors: Present and Future. Hematol Oncol Clin N Am 2005;19:69-85.
Owens C, Belkin M. Thrombosis and Coagulation: Operative Management of the Anticoagulated Patient. Surg Clin N Am 2005;85:1179-1189.
Frenkel E, Shen Y, Haley B. The Direct Thrombin Inhibitors: Their Role and Use for Rational Anticoagulation. Hematol Oncol Clin N Am 2005;19:119-145.
Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998;114:561S- 578S.
Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 2001;119(1):12.
Ansell J, Hirsh J, Poller L. The Seventh ACCP Conference on Antithrombotic and Thrombolitic Therapy: Evidence-Based Guidelines. Chest 2004;126(3).
Scazziota A, Altman R. El mecanismo de la hemostasia normal. Rev Iberoamer Trom Hemost 1994;7:95-109.
Shafer A. The hipercoagulable states. Ann Intern Med 1985;102:814-828.
Subar M. Thromboembolic disease and anticoagulation in the elderly. Clin Geriatric Med 2001;17(1).
Whiteman T, Hassouna H. Hypercoagulable states. Hematol/ oncol Clin North Am 2000;14(2).
De Estefano V, Finazzi G, Manucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood 1996;87:3531-3144.
Hirsh J, Fuster V. Guide to anticoagulant therapy: heparin. Circulation 1994;89:1449-1468.
Hyers T, Hull R, Weg J. Antithrombotic therapy for venous thromboembolic disease. Chest 1995;108:3355-3515.
Lobato-Mendizabal E, Majluf-Cruz A. Trombofilia, tromboembolia y el uso de las heparinas de bajo peso molecular. Rev Invest Clin 2000;52(5):529-545.
Bergqvist D, Benoni G, Björgell O, et al. Low-molecularweight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Eng J Med 1996;335(10):696-700.
Comp P, Spiro T, Friedman R, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. J Bone Joint Surg Am 2001;83(3):336- 349.
Bergqvist D, Agnelli G, Cohen A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Eng J Med 2002;346(13):975-980.
Hirsh J. The optimal duration of anticoagulant therapy for venous thrombosis. N Eng J Med 1995;332(25):1710-1712.
Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Eng J Med 1997;336(6):393-398.
Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992;152:1589-1595.
Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med 1993;119:874-881.
Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular- weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. TheTasman Study Group. N Engl J Med 1996;334:682-687.
Hull RD, Pineo GF, Valentine KA. Treatment and prevention of venous thromboembolism. Semin Thromb Hemost 1998;24 Suppl 1:21-31.
Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119:1088-1218.
Warkentin TE. Heparin-induced thrombocytopenia: a ten-year retrospective. Ann Rev Med 1999;50:129-147.
Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation 2001;103:1479-1484.
Booth SL, Centurelli MA. Vitamin K: a practical guide to the dietary management of patients on warfarin. Nutr Rev 1999;57:288-296.
Triplett DA. Current recommendations for warfarin therapy. Use and monitoring. Med Clin North Am 1998;82:601-611.
Weitz J, Hirsh J, Samara M. New Anticoagulant Drugs The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. Chest 2004;126.
Eriksson B, Borris L, Friedman R, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-2775.
Kakkar A, Brenner B, Dahl O, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double blind, randomized controlled trial. Lancet 2008;372:31-39.
Lassen M, Ageno W, Borris L, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-2786.
Turpie A, Bauer K, Davidson B, et al. Comparison of rivaroxaban- an oral direct Factor Xa inhibitor-and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD4: a phase III study). European Federation of National Associations of Orthopedics and Traumatology 2008 Meeting, 29 May-1 June 2008, Nice, France Abstract F85.
Eriksson B, Dahl O, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, noninferiority trial. Lancet 2007;370:949-956.
Eriksson B, Dahl O, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-2185.
Connolly S, Ezekowitz M, Phil, et al. Dabigatran versus Warfarin in patients with Atrial Fibrillation. N Engl J Med 2009; 361.
Schulman S, Kearon C, Kakkar A, et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med 2009;361:2342-2362.